Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23092423 | 1.00 | MEN1 (0.49) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL23092893 | 0.88 | NPC1 (0.52) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL23092894 | 0.88 | NPC1 (0.52) | MEN1KMT2AKDM4ENPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23092867 | 0.86 | NPC1 (0.51) | MEN1KMT2AKDM4ENPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23092868 | 0.86 | NPC1 (0.51) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL18435147 | 0.86 | GPR142 (0.57) | MEN1KMT2ANPC1RAB9AGPR142 | |
| SCHEMBL23092675 | 0.85 | SMN1; SMN2 (0.52) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL23092466 | 0.80 | BACE1 (0.55) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL23092470 | 0.80 | BACE1 (0.55) | MEN1KMT2AKDM4ENPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23093160 | 0.79 | BACE1 (0.54) | MEN1KMT2AKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | MEN1 3722/4885KMT2A 955/4885KDM4E 732/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MEN1 3722/4885KMT2A 955/4885KDM4E 732/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MEN1 3722/4885KMT2A 955/4885KDM4E 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.